Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $4.46.

Several equities research analysts have recently commented on SYN shares. William Blair restated an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a research note on Sunday, March 5th. Zacks Investment Research cut Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Friday, April 7th. Finally, ValuEngine cut Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of Synthetic Biologics (SYN) traded down 4.974% during midday trading on Tuesday, hitting $0.661. 1,713,533 shares of the stock were exchanged. The company’s market cap is $80.57 million. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.94. The firm has a 50 day moving average of $0.57 and a 200-day moving average of $0.71.

Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings results on Thursday, May 4th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.05. Equities analysts expect that Synthetic Biologics will post ($0.25) EPS for the current year.

WARNING: “Synthetic Biologics Inc (SYN) Given Consensus Rating of “Buy” by Brokerages” was first reported by Financial Market News and is the property of of Financial Market News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.financial-market-news.com/2017/06/18/synthetic-biologics-inc-syn-given-consensus-rating-of-buy-by-brokerages.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in SYN. Norges Bank acquired a new position in shares of Synthetic Biologics during the fourth quarter worth $356,000. MSD Partners L.P. raised its position in shares of Synthetic Biologics by 32.1% in the fourth quarter. MSD Partners L.P. now owns 4,118,402 shares of the company’s stock worth $3,141,000 after buying an additional 1,000,000 shares in the last quarter. State Street Corp raised its position in shares of Synthetic Biologics by 0.5% in the fourth quarter. State Street Corp now owns 954,323 shares of the company’s stock worth $727,000 after buying an additional 5,195 shares in the last quarter. UBS Group AG raised its position in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Synthetic Biologics by 2.7% in the first quarter. Geode Capital Management LLC now owns 551,538 shares of the company’s stock worth $347,000 after buying an additional 14,395 shares in the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.